Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $492.24M
• Dividend Yield: N/A
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: -17.37%
• EPS Growth: 52.28%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 384,565,400
• 10 Day Avg. Volume: 1,064,559
• 30 Day Avg. Volume: 1,279,002
• PEG Ratio: 0.10
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 3.54
• P/FCF Ratio: -4.07
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 3.03
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: -4.17
• 1Y Price Target: $1.35
• Price Target Upside: -4.26% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $1.50 ▲(6.38% Upside)

The score is held down primarily by weak financial performance (declining revenue, persistent losses, and negative operating/free cash flow) and limited valuation support due to negative earnings and no dividend data. Technical signals are mixed with modest positive MACD but soft recent trend versus short-term moving averages. The major divestiture and resulting cash increase is a meaningful positive offset but does not fully outweigh the current operating challenges.

Positive Factors

Low leverage / balance sheet flexibility

A very low debt-to-equity ratio reduces refinancing and interest risk and preserves financial optionality. Over the medium term this strengthens the company's ability to fund operations, withstand revenue volatility, and pursue disciplined M&A or capex without overleveraging the business.

Sustainable gross margin on products

A near-48% gross margin on instruments and consumables indicates structurally strong unit economics. If revenue stabilizes, these margins provide room to absorb SG&A and support a credible path to adjusted profitability, given the recurring consumables and service revenue mix typical in life-science tools.

Large pending cash inflow from SomaLogic sale

A roughly $550M cash infusion on closing is a structural capital event that materially improves liquidity and strategic optionality. It can fund the operating runway, enable targeted M&A, support R&D investment, and reduce dependence on dilutive financings while management pursues margin improvement.

Negative Factors

Declining revenue trend

A persistent ~16% annual revenue decline undermines operating leverage and makes fixed-cost absorption difficult. Long-term recovery requires reversing top-line erosion; otherwise margin gains and cost cuts may only temporarily mask structural demand issues across core instruments and consumables.

Negative operating and free cash flows

Continued negative operating and free cash flow means core operations are burning cash, limiting the company's ability to self-fund growth or sustain R&D and service investments. Without durable OCF improvement, the business will remain reliant on asset sales or external capital.

Persistent net losses and negative margins

Ongoing net losses and negative EBIT margins indicate the company has not reached operating profitability. Even with restructuring savings, sustained revenue recovery is needed to convert gross margin into positive operating profit; otherwise equity dilution or cash depletion risks persist.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue through the sale of its proprietary instruments, consumables, and software solutions. Key revenue streams include direct sales of lab equipment, such as the company's flagship products for single-cell analysis and multi-omics applications, as well as ongoing sales of consumable reagents required for these systems. The company also benefits from service contracts and maintenance agreements for its instruments. Additionally, Standard BioTools has established strategic partnerships with academic institutions, pharmaceutical companies, and research organizations, which can lead to collaborative projects, joint ventures, and potentially lucrative licensing agreements that further bolster its earnings.

Standard BioTools Financial Statement Overview

Summary

Income statement and cash flow are the main drags: revenue is declining (-16.48% TTM) with negative profitability (net profit/EBIT margins) and negative operating/free cash flow. The balance sheet is a partial offset with low leverage (debt-to-equity 0.069), but negative ROE underscores ongoing losses. KPI insights also point to volatile, one-off revenue drivers and weak sustained growth in core recurring streams.

Income Statement

Standard BioTools has faced declining revenue with a negative growth rate of -16.48% in the TTM. The company is struggling with profitability, as indicated by negative net profit and EBIT margins. Gross profit margin remains relatively stable at 47.94%, but the overall financial performance is hindered by significant losses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.069, indicating low leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a relatively strong equity position compared to its total assets.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, suggesting cash flow challenges. The free cash flow to net income ratio is above 1, indicating that free cash flow exceeds net income, but both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	128.83M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	61.76M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-93.61M	-118.14M	-54.46M	-173.57M	-44.27M	-34.60M
Net Income	-128.25M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	539.64M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	194.90M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	27.39M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	139.98M	140.62M	471.12M	471.78M	180.62M	185.71M
Stockholders Equity	399.66M	471.72M	-148.05M	-81.47M	94.60M	139.05M
Cash Flow
Free Cash Flow	-98.42M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-87.21M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	61.17M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-54.57M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.49, below the 50-day MA of 1.46, and above the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 36.36 is Neutral, neither overbought nor oversold. The STOCH value of 8.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$973.62M	15.88	24.11%	―	14.46%	―
CSTL	62 Neutral	$1.02B	-77.67	-2.69%	―	10.15%	-295.52%
FLGT	53 Neutral	$789.19M	-18.21	-3.80%	―	13.60%	74.64%
PSNL	53 Neutral	$737.96M	-9.49	-43.69%	―	-21.02%	47.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LAB	46 Neutral	$492.24M	-3.78	-24.63%	―	-17.37%	52.28%
MYGN	41 Neutral	$494.03M	-1.22	-72.52%	―	0.21%	-233.51%

Standard BioTools Corporate Events

Standard BioTools Completes Major Proteomics Business Divestiture

On January 30, 2026, Standard BioTools completed the sale of its aptamer-based and functional proteomics business, including SomaLogic and Sengenics entities and the SomaScan, KREX and Single SOMAmer assay franchises, to Illumina for $350 million in upfront cash and up to $75 million in performance-based earnout payments, for total potential proceeds of $425 million plus specified royalties. The divestiture, which leaves Standard BioTools retaining its mass cytometry and microfluidics operations, also gives the company 10-year royalty streams on SOMAmer-based NGS library preparation kits and Single SOMAmer sales and a co-exclusive license to Single SOMAmer IP, and has boosted its estimated cash and cash equivalents to about $550 million at closing, positioning the company to pursue inorganic growth and move its streamlined continuing operations toward positive adjusted EBITDA in 2026, while ending its direct economic participation in the prior SomaLogic-Illumina collaboration.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Implements Restructuring for Future Growth

Standard BioTools reported a third-quarter 2025 revenue of $19.6 million from continuing operations, marking an 11% decline year-over-year. The company has implemented a restructuring plan expected to save $40 million annually, with a goal of achieving positive adjusted EBITDA by 2026. The restructuring includes a 20% workforce reduction and consolidating operations to improve efficiency. The company anticipates a significant cash boost from a pending transaction with Illumina, which will support its growth strategy through mergers and acquisitions.

The most recent analyst rating on (LAB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.